Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) reached a new 52-week low during trading on Thursday . The company traded as low as $20.48 and last traded at $20.68, with a volume of 441458 shares. The stock had previously closed at $20.80. Wall Street Analysts Forecast Growth CERE has been the […]
Affinity Asset Advisors LLC raised its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 76.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,000 shares of the biotechnology company’s stock after purchasing an additional 165,000 shares during the […]
Profund Advisors LLC purchased a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 39,316 shares of the biotechnology company’s stock, valued at approximately $959,000. Other hedge funds and other institutional […]
Cerevel Therapeutics (NASDAQ:CERE – Free Report) had its price target decreased by Mizuho from $29.00 to $25.00 in a research report released on Monday, MarketBeat reports. Mizuho currently has a neutral rating on the biotechnology company’s stock. A number of other research analysts have also weighed in on the stock. Bank of America lowered shares […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) hit a new 52-week low on Friday after Morgan Stanley lowered their price target on the stock from $46.00 to $42.00. Morgan Stanley currently has an overweight rating on the stock. Cerevel Therapeutics traded as low as $22.58 and last traded at $22.75, with a volume […]